U.S. Trade Distributors Stock News

Arbutus Biopharma and Genevant Sciences have launched new patent lawsuits targeting lipid nanoparticle technology used in Pfizer BioNTech (NasdaqGS:BNTX) COVID-19 vaccines. The actions seek monetary damages and potential injunctions across Canada and multiple European countries. See our latest analysis for BioNTech. For investors, the latest lawsuits arrive after a weaker period for BioNTech’s stock, with the share price at US$92.95 and short term momentum softening following a 90 day share...

Archer Aviation stock has fallen sharply over the past year, yet on simple market multiples it still screens as undervalued, leaving investors weighing weak recent returns against a mixed but not outright negative valuation picture. Archer Aviation shares are down 55.9% over the past year, which signals that sentiment around the stock has been under pressure even as news flow has been active. The new autonomous aircraft platforms with Anduril and the infrastructure push under the ACES...

Earlier this week, UDR, Inc. raised its full-year 2026 net income guidance to a range of US$1.03 to US$1.11 per diluted share, up from its prior US$0.91 to US$1.01 range, and projected third-quarter 2026 net income of US$0.13 to US$0.15 per diluted share. The guidance increase followed stronger-than-expected second-quarter performance, underpinned by solid occupancy, record resident retention, ongoing share repurchases, and new development activity amid a reshaping of its debt and asset...

In recent weeks, U.S. Bancorp completed a series of fixed‑income offerings totaling several billion US$, issued mainly as callable senior unsecured notes with fixed coupons ranging from 5.05% to 6.15% and fixed‑to‑floating structures maturing between 2030 and 2046. Alongside these bond sales, the bank reported higher second‑quarter net interest income and net income year over year, raised its 2026 revenue guidance, and continued share repurchases, underscoring management’s confidence while...

Victoria's Secret (VSXY) raised its fiscal 2026 outlook after a strong first quarter, highlighting broad-based growth supported by data-driven digital marketing, customer analytics, and ongoing investments in customer acquisition. See our latest analysis for Victoria's Secret. At a share price of $89.13, Victoria's Secret has a 90 day share price return of 71.97% and a year to date share price return of 67.04%, while the 1 year total shareholder return of 356.61% reflects the market reaction...

Redwire recently secured a US$1.80 billion, 10-year contract with the U.S. Space Systems Command, underscoring its role in supplying critical space infrastructure to government customers. This long-term award materially strengthens Redwire’s contracted revenue base, offering greater visibility that may help counterbalance the company’s exposure to volatile, project-based government work. We’ll now examine how this long-term US$1.80 billion government contract could reshape Redwire’s...

Chemed stock jumped 4.2% to about US$539 by the close, which indicates that the market responded positively to the results, but the headline story runs deeper than a single-day move. Q2 adjusted earnings outpaced recent history, with adjusted diluted earnings per share up sharply year on year and VITAS hospice margins comfortably above internal expectations. For you as a shareholder, the key point is how those hospice economics influence the longer-term view. Forecast earnings growth, solid...

Procter & Gamble’s latest results have put fresh attention on how higher costs and softer volumes can affect even the largest consumer goods companies. Revenue came in at $21.2b, slightly below expectations, and management flagged a $1b after tax cost headwind and an estimated 8% drag on 2027 earnings guidance. For you as an investor, that kind of update can shift attention toward businesses that focus on private label and value products. This article looks at three stocks that appear exposed...

In the past week, SoFi Technologies reported second-quarter 2026 results with revenue rising to US$1,140.53 million and net income to US$156.59 million, while net charge-offs increased to US$204.51 million from US$160.28 million a year earlier. The company also raised its full-year revenue outlook and delivered record member and loan growth, even as it chose to reinvest incremental revenue rather than upgrade its profit guidance. Next, we’ll examine how record loan originations alongside...

Watsco, Inc. reported its Q2 2026 results with sales rising to US$2,104.86 million from US$2,062.44 million a year earlier, while net income declined to US$163.34 million from US$183.61 million and diluted EPS from continuing operations eased to US$4 from US$4.52. Alongside the mixed earnings, Watsco announced the acquisition of Jackson Supply Company, broadening its Sunbelt footprint as it continues investing in e-commerce, technology, and AI-driven tools to improve efficiency in the...

Dividend announcement and upcoming Q2 earnings Federal Signal (FSS) recently declared a quarterly cash dividend of $0.15 per share, payable on August 27, 2026, with investors needing to be on record by August 14, 2026. This dividend update arrives as Federal Signal prepares to report its Q2 2026 results and host an earnings call on July 30, 2026. These events may influence how you assess the stock’s income and growth profile. See our latest analysis for Federal Signal. At a share price of...

FirstEnergy stock slipped about 1% today, a muted reaction for a regulated utility that has been trading near the upper end of its recent range. The move understates the real tension in this quarter. The headline is not revenue or earnings per share; it is pressure on profitability at a time when investors already question how comfortably this balance sheet supports a premium P/E and a dividend that is not well covered by earnings. Q2 core earnings per share landed at about 50 cents and net...

Core Scientific entered this earnings report with a high growth story and a stock that had already been under pressure over the past month. The market’s initial reaction was clear, with the share price falling 12.65% to US$18.12 in regular trading after the results. The main headline is not revenue, which came in at US$164.2 million for the quarter. The focus is on the size of the loss. Core Scientific reported net income from ongoing operations excluding extra items of US$1.08b in the red...

Western New England Bancorp came into this earnings season with a reputation as a slow and steady regional lender, yet the stock just dropped roughly 12% in a single session. That is a sharp move for a community bank that has been posting solid trailing profit margins. The headline this quarter is pressure on profitability. Quarterly basic earnings per share landed at US$0.18 on revenue of US$21.16m, both lower than recent runs, which jarred a market that had been treating the stock as a...

Vertex Pharmaceuticals stock reaction to new AbCellera collaboration Vertex Pharmaceuticals (VRTX) drew fresh attention after AbCellera Biologics announced a collaboration to develop multispecific T cell engagers for autoimmune diseases. Under the agreement, Vertex will fund research and retain rights to advance and commercialize the resulting therapies. See our latest analysis for Vertex Pharmaceuticals. For context, Vertex Pharmaceuticals shares are at US$483.33, with a 90 day share price...

Amphenol Corporation has already reported second-quarter 2026 results, with sales rising to US$8.76 billion and net income to US$1.77 billion, alongside higher earnings per share versus a year earlier, and issued third-quarter 2026 sales guidance of US$9.3 billion to US$9.4 billion, above prior-year levels. The company’s outperformance was driven by strong AI-related IT datacom demand and contributions from recent acquisitions, which together lifted all three operating segments above...

Arcutis Biotherapeutics, Inc. recently appointed Christopher “Chris” Peetz, co-founder and CEO of Mirum Pharmaceuticals, to its Board of Directors, bringing extensive biopharmaceutical, finance, and M&A experience to the company. His background in scaling rare-disease platforms, executing acquisitions, and serving on boards through successful exits may influence how Arcutis shapes its growth, partnerships, and capital allocation decisions. Next, we’ll examine how adding Peetz’s rare-disease...

Delek US Holdings stock has turned a US$1 investment five years ago into roughly US$4 today, yet the company still screens as cheap on Simply Wall St’s valuation checks. After such a strong run, investors are weighing whether the recent share price strength has already captured that value gap or if there is still room based on fundamentals. Over the past 5 years, Delek US Holdings has delivered a very large total return of about 359.7%, which puts the current share price into sharper focus...

Atlantic Union Bankshares (AUB) is back on investor radar after reporting sharply higher net income and earnings per share for the second quarter and first half of 2026, alongside active capital return moves. See our latest analysis for Atlantic Union Bankshares. At a share price of $42.62, Atlantic Union Bankshares has a 90 day share price return of 13.2% and a 1 year total shareholder return of 37.82%. This suggests momentum has been building as investors respond to stronger earnings,...

JetBlue Airways has returned 27.4% over the past year and is up 24.6% year to date, yet over five years the stock is still down 60.5%. This leaves many investors asking whether the current price around US$5.72 reflects a genuine turnaround or just a rebound from a much lower base. At the same time, Simply Wall St's valuation checks point to JetBlue screening as undervalued on the broader metrics, even as recent headlines highlight both progress and ongoing pressure on profitability. Over the...

Humana stock has delivered a strong 41.8% return over the past year, yet its valuation checks and market multiples point to a more mixed picture rather than a straightforward bargain or bubble. Over the last 12 months, Humana has returned 41.8%, which puts recent share price weakness into context for investors assessing whether the move has already priced in a lot of good news. Humana's valuation can be influenced by how consistently it converts revenue into cash flow, while any sustained...

DXC Technology (DXC) stock is back in focus after the company deepened its push into AI, announcing a new partnership with voice AI specialist ElevenLabs and confirming participation in ElevenLabs’ recent $500 million funding round. See our latest analysis for DXC Technology. The ElevenLabs partnership and recent AI leadership changes come as DXC Technology’s share price has jumped, with a 1 week share price return of 25.08% and 1 month share price return of 32.84%. However, the year to date...

Summit Therapeutics has reported a reduced net loss for the second quarter of 2026 and filed for a US$380 million at-the-market equity offering, while also highlighting updated overall survival data from its Phase III HARMONi trial of ivonescimab and entering a new kidney cancer trial collaboration with Arcus Biosciences. The combination of encouraging HARMONi survival trends, an expanded clinical footprint into metastatic kidney cancer, and fresh equity financing underscores how central...

GEO Group (NYSE:GEO) has secured a five year contract with U.S. Immigration and Customs Enforcement for exclusive use of its Rivers Facility in North Carolina. The facility will operate as a federal immigration processing center under the new agreement. This development adds a new source of recurring contract revenue that had not been covered in prior GEO Group news focused on the Big Horn Facility. GEO Group operates private correctional, detention, and community reentry facilities, and...